Vaxxinity | search
Click here to view Vaxxinity news from 60+ newspapers.
Bookmark or Share- Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD ...CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International ...
- News Releases - VaxxinityCAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program
- VaxxinityVaxxinity, Inc. is no longer subject to reporting requirements under the Exchange Act or those required by the listing standards of a national securities exchange, the provisions of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”), or the rules of the U.S. Securities and Exchange Commission (the “SEC”) applicable to ...
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results ...Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer ...
- Vaxxinity Issues Shareholder Letter | VaxxinityTo Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longer be publicly traded on the NASDAQ exchange.
More
